🇪🇺 Efalizumab (Raptiva) in European Union

EMA authorised Efalizumab (Raptiva) on 20 September 2004

Marketing authorisation

EMA — authorised 20 September 2004

  • Application: EMEA/H/C/000542
  • Marketing authorisation holder: Serono Europe Limited
  • Local brand name: Raptiva
  • Indication: Treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA (see section 5.1 - Clinical Efficacy).
  • Status: withdrawn

Read official source →

Other Immunology/Dermatology approved in European Union

Frequently asked questions

Is Efalizumab (Raptiva) approved in European Union?

Yes. EMA authorised it on 20 September 2004.

Who is the marketing authorisation holder for Efalizumab (Raptiva) in European Union?

Serono Europe Limited holds the EU marketing authorisation.